Reposted by Padraig Dixon
(3/4) @padraigdixon.bsky.social (University of Oxford) will present a novel approach to estimate long-term cost-effectiveness of health interventions without RCTs/Markov models. Using a prostate cancer prevention case study, he’ll show how MR can link genetic liability to healthcare costs & QALYs.
Reposted by Padraig Dixon
Modelling the potential contributions of polygenic risk stratification to cost-effective screening for prostate cancer https://www.medrxiv.org/content/10.1101/2025.05.19.25327897v1
Reposted by Padraig Dixon
#january Day 5
As #genomic testing evolves, what does this mean for risk-rated #insurance? This article led by former CPM JRF @padraigdixon.bsky.social discusses emerging challenges:
As #genomic testing evolves, what does this mean for risk-rated #insurance? This article led by former CPM JRF @padraigdixon.bsky.social discusses emerging challenges:
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges | Health Economics, Policy and Law | Cambridge Core
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges
buff.ly
The changing landscape of genetics and insurance in the UK - report on an event hosted by the Centre for Personalised Medicine, Oxford and the British Society for Genetic Medicine. bsgm.org.uk/media/12689/...
bsgm.org.uk